Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00775658 · ClinicalTrials.gov registry record · NA
Olopatadine Eye Drops and Allergy Skin Testing
A NA study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00775658: Completed NA study, sponsored by Vanderbilt University Medical Center.
NCT00775658 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00775658, a NA study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.
Interventions
- DRUG placebo
- DRUG olopatadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-06 |
| Phase | NA |
What the finished NCT00775658 record still lists
NCT00775658 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00775658 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00775658 about?
NCT00775658 is a clinical study titled "Olopatadine Eye Drops and Allergy Skin Testing". Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.
What is the current status of trial NCT00775658?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2008-01. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00775658?
The interventions under investigation include: placebo (DRUG), olopatadine (DRUG).
Who is sponsoring clinical trial NCT00775658?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00775658's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia